Diagnostic assay and treatment for preeclampsia
US11065222B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 19, 2019 |
| Grant date | Jul 20, 2021 |
| Priority date | — |
| Expiry date | Jul 19, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/368
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.